143 related articles for article (PubMed ID: 25604134)
41. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
42. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
43. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
Lara PN; Longmate J; Mack PC; Kelly K; Socinski MA; Salgia R; Gitlitz B; Li T; Koczywas M; Reckamp KL; Gandara DR
Clin Cancer Res; 2015 Oct; 21(19):4321-6. PubMed ID: 26106072
[TBL] [Abstract][Full Text] [Related]
44. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
[TBL] [Abstract][Full Text] [Related]
45. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Riely GJ
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
[TBL] [Abstract][Full Text] [Related]
46. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Scagliotti GV; Novello S; Schiller JH; Hirsh V; Sequist LV; Soria JC; von Pawel J; Schwartz B; Von Roemeling R; Sandler AB
Clin Lung Cancer; 2012 Sep; 13(5):391-5. PubMed ID: 22440336
[TBL] [Abstract][Full Text] [Related]
47. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
48. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
49. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
[TBL] [Abstract][Full Text] [Related]
50. Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.
Anderson JC; Swede H; Rustagi T; Protiva P; Pleau D; Brenner BM; Rajan TV; Heinen CD; Levine JB; Rosenberg DW
Cancer Causes Control; 2012 Feb; 23(2):355-61. PubMed ID: 22187142
[TBL] [Abstract][Full Text] [Related]
51. Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model.
Tsuda M; Okamoto K; Muguruma N; Sannomiya K; Nakagawa T; Miyamoto H; Kitamura S; Goji T; Kimura T; Okahisa T; Izumi K; Takayama T
J Gastroenterol Hepatol; 2013 Oct; 28(10):1616-23. PubMed ID: 23730936
[TBL] [Abstract][Full Text] [Related]
52. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
53. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
Efferth T
Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
[TBL] [Abstract][Full Text] [Related]
54. Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial.
Kwan AK; Um CY; Rutherford RE; Seabrook ME; Barry EL; Fedirko V; Baron JA; Bostick RM
Mol Carcinog; 2019 Apr; 58(4):511-523. PubMed ID: 30499618
[TBL] [Abstract][Full Text] [Related]
55. Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.
Omachi K; Miyakita R; Fukuda R; Kai Y; Suico MA; Yokota T; Kamura M; Shuto T; Kai H
Clin Exp Nephrol; 2017 Dec; 21(6):952-960. PubMed ID: 28176019
[TBL] [Abstract][Full Text] [Related]
56. Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial.
Higurashi T; Ashikari K; Tamura S; Saigusa Y; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Kessoku T; Hosono K; Yoneda M; Nakajima A
Cancer Prev Res (Phila); 2022 Oct; 15(10):661-668. PubMed ID: 36083855
[TBL] [Abstract][Full Text] [Related]
57. Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk.
Quintanilla I; López-Cerón M; Jimeno M; Cuatrecasas M; Zabalza M; Moreira L; Alonso V; Rodríguez de Miguel C; Muñoz J; Castellvi-Bel S; Llach J; Castells A; Balaguer F; Camps J; Pellisé M
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00047. PubMed ID: 31136360
[TBL] [Abstract][Full Text] [Related]
58. Effects of Supplemental Calcium and Vitamin D on Expression of Toll-Like Receptors and Phospho-IKKα/β in the Normal Rectal Mucosa of Colorectal Adenoma Patients.
Hodge R; Mandle HB; Ray S; Tandon S; Peterson M; Henry A; Jahan FA; Bostick RM; Baron JA; Barry EL; Yacoub R; Rutherford RE; Seabrook ME; Fedirko V
Cancer Prev Res (Phila); 2018 Nov; 11(11):707-716. PubMed ID: 30209117
[TBL] [Abstract][Full Text] [Related]
59. DNA methylation in the rectal mucosa is associated with crypt proliferation and fecal short-chain fatty acids.
Worthley DL; Whitehall VL; Le Leu RK; Irahara N; Buttenshaw RL; Mallitt KA; Greco SA; Ramsnes I; Winter J; Hu Y; Ogino S; Young GP; Leggett BA
Dig Dis Sci; 2011 Feb; 56(2):387-96. PubMed ID: 20635146
[TBL] [Abstract][Full Text] [Related]
60. Resistant starch supplementation increases crypt cell proliferative state in the rectal mucosa of older healthy participants.
Malcomson FC; Willis ND; McCallum I; Xie L; Ouwehand AC; Stowell JD; Kelly S; Bradburn DM; Belshaw NJ; Johnson IT; Mathers JC
Br J Nutr; 2020 Aug; 124(4):374-385. PubMed ID: 32279690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
